FDA Extends Review Period for Quizartinib for Adults With FL

Daiichi Sankyo announced that the new deadline for review of the application is July 24, 2023.

Related Keywords

United States , American , Daiichi Sankyo , Mark Rutstein , Mikkael Sekeres , University Of Miami Health System , American Cancer Society , European Hematology Association Congress , Oncology Clinical Development , Prescription Drug User Fee Act , Risk Evaluation , Mitigation Strategies , American Cancer , Global Head , Hematology Association Congress , Sylvester Comprehensive Cancer Center , Miami Health System , Aml , Acute Myeloid Leukemia , Quizartinib ,